Sickle Cell Disease
Conditions
Brief summary
A randomized control trial in 20 subjects with sickle cell disease comparing oral THU-decitabine to nicotinamide and in combination (THU, decitabine and nicotinamide).
Detailed description
A randomized control trial comparing oral THU-decitabine to nicotinamide (1:1 randomization), and then comparing the effects of the combination of nicotinamide with THU-decitabine vs either treatment alone. Treatment with each agent alone is for 12 weeks followed by the combination for a further 12 weeks. Patients have the option to enter an extension phase of combination treatment for an additional 24 weeks (total of 48 weeks)
Interventions
DRUGNicotinamide
Oral nicotinamide (Vitamin B3) alone compared to THU Decitabine combination
Sponsors
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
EpiDestiny, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
1:1 Randomization
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 18 years or older. * Written informed consent provided by the subject before study entry. * Confirmed sickle cell disease (SCD) as determined by hemoglobin electrophoresis or liquid chromatography. * Subject is in his/her steady state and not having any acute complication due to SCD (i.e., hospitalization, acute pain, or acute chest syndrome in the past 14 days). * Weight at least 40kg * Regular compliance with comprehensive care and previous therapy. * Symptomatic SCD is defined as having one of following, despite at least 6 months of hydroxyurea therapy, or refuse to take hydroxyurea for personal reasons: fetal hemoglobin \<0.5 g/dL, or 3 or more pain episodes per year requiring parenteral narcotics, or 1 or more acute chest syndrome episodes, or Hemoglobin \<9 g/dL and absolute reticulocyte count \<250,000/mm3.
Exclusion criteria
* Inability to give informed consent. * Experienced severe sepsis or septic shock within the previous 12 weeks. * Last HU dose was ingested within the previous 4 weeks. * Currently pregnant or breast-feeding. * Alanine Aminotransferase (ALT) ≥ 3 times the upper limit of normal or albumin \<2.0 mg/dL or direct (conjugated) bilirubin ≥ 1.5 mg/dl. * Serum creatinine \>2.9 mg/dL and calculated creatinine clearance \<30 mL/min. * Platelet count \>800 x 109/L. * Absolute neutrophil count \<1.5 x 109/L. * Female of active childbearing potential who is unwilling to use at least one of the two following forms of birth control: (i) not having heterosexual sexual contact beginning at the screening visit and continuing until 4 weeks after the last dose of decitabine OR (ii) intrauterine device (IUD). * Sexually active male who is unwilling to use a condom when engaging in any sexual contact with a female with child-bearing potential, beginning at the screening visit and continuing until 4 weeks after taking the last dose of THU and decitabine. This requirement applies also to males who have had a successful vasectomy. * Altered mental status or recurrent seizures requiring anti-seizure medications. * Moribund or any concurrent disease (e.g., hepatic, renal, cardiac, metabolic) of such severity that death within 24 weeks is likely. * Concurrent diagnosis of malignancy including known Myelodysplastic syndrome, leukemia, or an abnormal karyotype. * New York Heart Association (NYHA) class III/IV status. * Eastern Co-operative Oncology Group (ECOG) performance status ≥3. * Participant is on chronic transfusion therapy * Known history of illicit drug or alcohol abuse within the past 12 months. * Other experimental or investigational drug therapy in the past 28 days. * Taking l-glutamine within the last 28 days * Being positive for HIV infection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Blood Hemoglobin | 12 weeks | Measure hemoglobin function |
Countries
United States
Contacts
Primary ContactLani Krauz
Outcome results
None listed